SE429551B - Sett att framstella 1-(3-dimetylamino-propyl)-ftalanderivat - Google Patents

Sett att framstella 1-(3-dimetylamino-propyl)-ftalanderivat

Info

Publication number
SE429551B
SE429551B SE7614201A SE7614201A SE429551B SE 429551 B SE429551 B SE 429551B SE 7614201 A SE7614201 A SE 7614201A SE 7614201 A SE7614201 A SE 7614201A SE 429551 B SE429551 B SE 429551B
Authority
SE
Sweden
Prior art keywords
phthaland
dimethylamino
propyl
derivatives
prepare
Prior art date
Application number
SE7614201A
Other languages
English (en)
Swedish (sv)
Other versions
SE7614201L (sv
Inventor
K P Bogeso
A S Toft
Original Assignee
Kefalas As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9722860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE429551(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kefalas As filed Critical Kefalas As
Publication of SE7614201L publication Critical patent/SE7614201L/xx
Publication of SE429551B publication Critical patent/SE429551B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SE7614201A 1976-01-14 1976-12-17 Sett att framstella 1-(3-dimetylamino-propyl)-ftalanderivat SE429551B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1486/76A GB1526331A (en) 1976-01-14 1976-01-14 Phthalanes

Publications (2)

Publication Number Publication Date
SE7614201L SE7614201L (sv) 1977-07-15
SE429551B true SE429551B (sv) 1983-09-12

Family

ID=9722860

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7614201A SE429551B (sv) 1976-01-14 1976-12-17 Sett att framstella 1-(3-dimetylamino-propyl)-ftalanderivat

Country Status (19)

Country Link
US (1) US4136193A (fr)
JP (1) JPS52105162A (fr)
AT (1) AT359488B (fr)
AU (1) AU509445B2 (fr)
BE (1) BE850401A (fr)
CA (1) CA1094087A (fr)
CH (3) CH626886A5 (fr)
DE (1) DE2657013C2 (fr)
DK (1) DK143275C (fr)
ES (1) ES454980A1 (fr)
FI (1) FI63754C (fr)
FR (1) FR2338271A1 (fr)
GB (1) GB1526331A (fr)
IE (1) IE44055B1 (fr)
NL (2) NL192451C (fr)
NO (2) NO147243C (fr)
NZ (1) NZ183001A (fr)
SE (1) SE429551B (fr)
ZA (1) ZA7757B (fr)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602035A (en) * 1983-12-07 1986-07-22 Hoechst-Roussel Pharmaceuticals Inc. Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
PT759299E (pt) * 1995-08-16 2000-09-29 Lilly Co Eli Potenciacao da resposta de serotonina
JP3526581B2 (ja) 1997-07-08 2004-05-17 ハー・ルンドベック・アクティーゼルスカブ シタロプラムの製造方法
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
CN1286687A (zh) * 1997-11-11 2001-03-07 H·隆德贝克有限公司 制备西酞普兰的方法
WO2000023431A1 (fr) 1998-10-20 2000-04-27 H. Lundbeck A/S Methode de preparation du citalopram
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
HRP20010418A2 (en) 1998-12-08 2002-06-30 Lundbeck & Co As H Benzofuran derivatives, their preparation and use
HK1043130B (zh) 1998-12-23 2005-03-04 H‧隆德贝克有限公司 制备5-氰基2-苯并[c]呋喃酮的方法
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
IL145615A0 (en) * 1999-04-14 2002-06-30 Lundbeck & Co As H Method for the preparation of citalopram
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991486A1 (it) * 1999-07-06 2001-01-06 Vis Farmaceutici S P A Processo per la sintesi di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB2360281B (en) 1999-10-25 2002-01-16 Lundbeck & Co As H Method for the preparation of citalopram
HK1043129B (zh) 1999-10-25 2004-10-21 H‧隆德贝克有限公司 西酞普蘭的製備方法
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
US6310222B1 (en) 1999-11-01 2001-10-30 Sumika Fine Chemicals Co., Ltd. Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
NZ519739A (en) 1999-12-28 2004-03-26 H Method for the preparation of citalopram
PT1246813E (pt) * 1999-12-30 2004-02-27 Lundbeck & Co As H Metodo para a preparacao de citalopram
WO2001051477A1 (fr) * 2000-01-14 2001-07-19 H. Lundbeck A/S Procede de preparation de 5-cyanophthalide
US6433196B1 (en) 2000-02-17 2002-08-13 Sumika Fine Chemicals Co., Ltd. Production method of citalopram, intermediate therefor and production method of the intermediate
NL1017415C1 (nl) * 2000-02-24 2001-05-18 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
IES20010143A2 (en) * 2000-02-24 2001-07-25 Lundbeck & Co As H Method for the preparation of citalopram
IES20010157A2 (en) * 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
BR0109364A (pt) * 2000-03-13 2002-12-24 Lundbeck & Co As H Métodos para fabricação de citalopram através de alquilação escalonada de 5-substituìda 1- (4-fluorofenil) - 1,3- diidroisobenzofuranos e citalopram
NL1017500C1 (nl) 2000-03-13 2001-04-26 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
SK14602002A3 (sk) 2000-03-13 2003-02-04 H. Lundbeck A/S Spôsob výroby citalopramu a medziprodukty
IL151488A0 (en) 2000-03-14 2003-04-10 Lundbeck & Co As H Method for the preparation of citalopram
TR200202168T2 (tr) * 2000-03-16 2002-12-23 H. Lundbeck A/S 5-Siyano-1-(4-Florofenil)-1,3-Dihidroizobenzofuranların preparasyon metodu
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US6977306B2 (en) 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
KR100821912B1 (ko) * 2000-05-12 2008-04-16 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조 방법
SK3362002A3 (en) * 2000-07-06 2002-08-06 Lundbeck & Co As H Method for the preparation of citalopram
HUP0302778A3 (en) * 2000-07-21 2005-02-28 Lundbeck & Co As H Novel compounds and their use as glycine transport inhibitors
CA2353693C (fr) * 2000-08-10 2003-07-22 H. Lundbeck A/S Compositions pharmaceutiques contenant du citaloprame
IL144816A (en) * 2000-08-18 2005-09-25 Lundbeck & Co As H Method for the preparation of citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
IT1319686B1 (it) * 2000-12-12 2003-10-23 C D Farmasint S R L Procedimento di preparazione di citalopram.
TR200201166T1 (tr) * 2000-12-22 2002-10-21 H.Lundbecks A/S Saf sitalopram hazırlanması için yöntem
DE10164725B4 (de) * 2000-12-28 2004-08-26 H. Lundbeck A/S Verfahren zur Herstellung von gereinigtem Citalopram
JP2003519121A (ja) * 2000-12-28 2003-06-17 ハー・ルンドベック・アクチエゼルスカベット 純粋なシタロプラムの製造方法
DE10112828C1 (de) * 2000-12-28 2002-11-21 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram
AU2001100195B4 (en) * 2001-01-05 2001-12-20 H Lundbeck As Pharmaceutical composition containing citalopram.
CA2435925A1 (fr) * 2001-01-30 2002-08-08 Orion Corporation Fermion Procede de preparation de 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
WO2002066453A1 (fr) * 2001-02-22 2002-08-29 Natco Pharma Limited Procede de preparation de citalopram
GB0105627D0 (en) * 2001-03-07 2001-04-25 Cipla Ltd Preparation of phthalanes
HRP20030811A2 (en) * 2001-03-09 2005-08-31 Ranbaxy Laboratories Limited Process for the preparation of citalopram
CA2445843A1 (fr) * 2001-05-01 2002-11-07 H. Lundbeck A/S Utilisation d'escitalopram pur enantiomere
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
IN192057B (fr) * 2001-07-19 2004-02-14 Ranbaxy Lab Ltd
ATE352546T1 (de) * 2001-07-31 2007-02-15 Lundbeck & Co As H Kristalline zusammensetzung enthaltend escitalopram
EP1288211A1 (fr) * 2001-08-28 2003-03-05 Sekhsaria Chemicals Ltd. Procédé amélioré pour la préparation d'hydrobromure de Citalopram à partir de 5-bromophthalide
US6967259B2 (en) * 2001-09-24 2005-11-22 Pharmachem Technologies Limited Process for the preparation of Citalopram intermediate
AU2002342045C1 (en) * 2001-10-12 2009-07-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin Vla antagonists
IN192863B (fr) * 2001-11-13 2004-05-22 Ranbaxy Lab Ltd
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
WO2003057132A2 (fr) * 2002-01-07 2003-07-17 Sun Pharmaceutical Industries Limited Procede de preparation de 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurane carbonitrile
GB2385848A (en) * 2002-02-27 2003-09-03 Cipla Ltd Citalopram salts
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
GB2387844B (en) * 2002-02-27 2005-05-11 Matrix Lab Ltd Separation of impurities from a crude mixture of citalopram
EP1346989A1 (fr) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Procede ameliore de preparation de citalopram et de bromhydrate de citalopram
US7196224B2 (en) * 2002-03-27 2007-03-27 Bando Chemical Industries, Ltd. 1,3,5-tris(arylamino)benzenes
CA2381341A1 (fr) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Methode de preparation et intermediaires connexes pour la synthese de l'escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
AR040970A1 (es) * 2002-08-12 2005-04-27 Lundbeck & Co As H Metodo para la separacion de intermediarios que pueden ser utilizados para la preparacion de escitalopram
WO2004016602A1 (fr) * 2002-08-14 2004-02-26 Natco Pharma Limited Procede de preparation de citalopram haute purete et de ses sels pharmaceutiquement acceptables
GB2385051B (en) * 2002-08-29 2003-12-24 Max India Ltd Improved process for the preparation of 5-substituted-1 (4-fluorophenyl)-1,3-dihydro isobenzofurans
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
NZ540281A (en) * 2002-12-23 2008-07-31 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
AU2003242990A1 (en) * 2003-01-17 2004-08-13 Pulla Reddy Muddasani Processes for the preparation of escitalopram and its precursor
EP1603548A4 (fr) * 2003-02-05 2007-10-10 Myriad Genetics Inc Composition et methode de traitement de troubles neurodegeneratifs
ITMI20030479A1 (it) * 2003-03-13 2004-09-14 Adorkem Technology S P A Procedimento per la preparazione di un ciano-isobenzofurano.
EP1486492A3 (fr) * 2003-06-10 2005-02-23 Sun Pharmaceuticals Industries Ltd. Un procédé de hydrogenolyse de [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofurane
WO2005065069A2 (fr) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
GB0317475D0 (en) * 2003-07-25 2003-08-27 Meditab Specialities Pvt Ltd Product
ITFI20030202A1 (it) * 2003-07-28 2005-01-29 Synteco Spa Processo per la preparazione di derivati del
SG146683A1 (en) * 2003-09-17 2008-10-30 Janssen Pharmaceutica Nv Fused heterocyclic compounds as serotonin receptor modulators
PT1506963E (pt) * 2003-10-28 2005-08-31 Adorkem Technology Spa Processo para a preparacao de citalopram
WO2005042473A1 (fr) * 2003-10-28 2005-05-12 Wockhardt Limited Procede ameliore de preparation d'hydrobromure de citalopram
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US8304431B2 (en) * 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
WO2005077927A1 (fr) * 2004-02-16 2005-08-25 Jubilant Organosys Limited Synthese « one-pot » de citalopram a partir de 5-cyanophthalide
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
ITMI20040717A1 (it) * 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
WO2006001877A2 (fr) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
EP1737473A4 (fr) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Combinaisons de lithium et utilisations associees
WO2005108683A1 (fr) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Placages pour parois, murs de soutenement et analogues
CA2618985A1 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
WO2006020852A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
WO2006020850A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
KR101166280B1 (ko) * 2004-08-23 2013-11-27 썬 파마 글로벌 에프제트이 시탈로프램 및 에난티오머의 제조 방법
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
CN104922117A (zh) 2005-03-22 2015-09-23 阿泽范药品公司 用于治疗月经前病症的β-内酰氨基链烷酸
WO2006103550A1 (fr) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Processus de preparation du citalopram et son intermediaire, le 5-aminophthalide
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
EP1879875A1 (fr) * 2005-04-22 2008-01-23 Wyeth Formes cristallines de {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}chlorhydrate amine
WO2006116151A1 (fr) * 2005-04-22 2006-11-02 Wyeth Derives d’alcanamine de benzofuranyle et leurs utilisations comme agonistes 5-ht2c
TW200718692A (en) 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
WO2007008758A2 (fr) 2005-07-08 2007-01-18 Braincells, Inc. Methodes destinees a identifier des agents et des conditions modulant la neurogenese
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
CA2615813C (fr) * 2005-07-19 2015-12-15 Azevan Pharmaceuticals, Inc. Antagonistes la vasopressine, du type beta-lactamyl phenylalanine, cysteine et serine
CA2615063A1 (fr) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. Formes posologiques et preparations a charge medicamenteuse elevee
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
WO2007047978A2 (fr) 2005-10-21 2007-04-26 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
US20090247772A1 (en) * 2005-11-14 2009-10-01 H. Lundbeck A/S Method for the Preparation of Escitalopram
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (fr) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation de neurogenese par des agents nootropes
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2021000A2 (fr) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2046119A2 (fr) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Traitement de troubles psychiatriques
WO2008059514A2 (fr) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Procédé de préparation d'escitalopram
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008030651A1 (fr) * 2006-09-08 2008-03-13 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
WO2008034032A2 (fr) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Modulateurs du récepteur cannabinoïde de type bêta-lactame
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2066355A2 (fr) * 2006-09-19 2009-06-10 Braincells, Inc. Combinaison comprenant un agent ppar et un deuxième agent neurogène pour le traitement d'une maladie du système nerveux central, pour augmenter la différentiation neuronale et pour augmenter la neurogenèse
JP4927497B2 (ja) * 2006-10-25 2012-05-09 株式会社シスコ 無湿乾燥用ホッパー装置
CN100457747C (zh) * 2006-11-21 2009-02-04 浙江大学 抗抑郁药西酞普兰关键中间体5-氰基苯酞的制备工艺
WO2008083204A2 (fr) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation de la neurogenèse par des ligands mélatoninergiques
CA2675132A1 (fr) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation de la neurogenese en utilisant du modafinil
EP1988086B2 (fr) 2007-04-23 2014-11-26 Synthon B.V. Processus pour résoudre un citalopram
JP2010527345A (ja) * 2007-05-18 2010-08-12 シプラ・リミテッド エスシタロプラムの調製方法
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (fr) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Procédé de préparation d'escitalopram
US8022232B2 (en) * 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
KR101103118B1 (ko) * 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2116231A1 (fr) 2008-05-07 2009-11-11 Hexal Ag Granulé comprenant de l'oxalate d'escitalopram
US20100087664A1 (en) * 2008-10-07 2010-04-08 Ravindra Vedantham Preparation of citalopram and salts thereof
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ME03452B (fr) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disubstitué octahy - dropyrrolo [3,4-c] pyrroles en tant que modulateurs du récepteur de l'orexine
AU2011272738B2 (en) 2010-07-01 2015-08-20 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
WO2013081567A1 (fr) 2011-12-02 2013-06-06 Mahmut Bilgic Formulations antipsychotiques effervescentes
WO2013100870A1 (fr) 2011-12-02 2013-07-04 Mahmut Bilgic Nouvelles compositions antipsychotiques
WO2013110313A1 (fr) * 2012-01-23 2013-08-01 H. Lundbeck A/S Modulateurs allostériques sélectifs du transporteur de la sérotonine
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
KR20230116948A (ko) * 2016-03-10 2023-08-04 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
KR102790657B1 (ko) 2017-09-15 2025-04-02 아제반 파마슈티칼스, 인코퍼레이티드 뇌 손상을 치료하기 위한 조성물 및 방법
EP3999058A4 (fr) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. Régimes de traitement non sédatifs à base de dexmédétomidine
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (fr) * 1965-03-18

Also Published As

Publication number Publication date
SE7614201L (sv) 1977-07-15
CH632259A5 (de) 1982-09-30
DK13177A (da) 1977-07-15
AU2107377A (en) 1978-07-13
NL192451B (nl) 1997-04-01
NL970031I1 (nl) 1997-10-01
FR2338271B1 (fr) 1982-11-05
CH632258A5 (de) 1982-09-30
DE2657013A1 (de) 1977-07-28
IE44055B1 (en) 1981-07-29
NO147243C (no) 1983-03-02
FI63754B (fi) 1983-04-29
GB1526331A (en) 1978-09-27
US4136193A (en) 1979-01-23
CH626886A5 (fr) 1981-12-15
FI770073A7 (fr) 1977-07-15
AU509445B2 (en) 1980-05-15
NL192451C (nl) 1997-08-04
JPS6135986B2 (fr) 1986-08-15
NL970031I2 (nl) 1997-10-01
NL7700244A (nl) 1977-07-18
JPS52105162A (en) 1977-09-03
NO147243B (no) 1982-11-22
IE44055L (en) 1977-07-14
FR2338271A1 (fr) 1977-08-12
DK143275B (da) 1981-08-03
FI63754C (fi) 1983-08-10
NZ183001A (en) 1978-06-02
ATA947276A (de) 1980-04-15
DE2657013C2 (de) 1985-11-14
CA1094087A (fr) 1981-01-20
NO770109L (no) 1977-07-15
AT359488B (de) 1980-11-10
ZA7757B (en) 1977-11-30
BE850401A (fr) 1977-07-14
ES454980A1 (es) 1978-04-01
NO1996001I1 (no) 1996-01-05
DK143275C (da) 1982-01-18

Similar Documents

Publication Publication Date Title
SE440779B (sv) Sett att framstella androstan-17-on-derivat
SE431935B (sv) Sett att framstella drageer
SE434957B (sv) Sett att framstella lagerkomponenter
SE7801537L (sv) Sett att framstella pyrrolidinderivat
SE441042B (sv) Sett att pavisa rheumatoida faktorer
SE435928B (sv) Sett att framstella nya 3-aryl-oxazolidin-2-oner
SE432256B (sv) Sett att framstella cellulosaalkyletrar
SE430687B (sv) Sett att framstella hexanitrostilben
SE425321B (sv) Sett att reducera vanadinoxider
SE420732B (sv) Sett att framstella 4-gonen-3-oner
SE436037B (sv) Sett att framstella nya 11-desoxi-prostaglandin-f?712-derivat
SE434397B (sv) Sett att framstella bens-acyl-bensimidazol-2-derivat
SE409162B (sv) Sett att sa skogsfro i humustecke
SE430505B (sv) Sett att framstella en substituerad purin
SE433213B (sv) Sett att framstella 2 -fenyl-3-amino-benso/b/tiofenderivat
SE431324B (sv) Sett att framstella trifenylalkaenderivat
SE420731B (sv) Sett att framstella 5-androsten-17-on-derivat
SE7713906L (sv) Sett att framstella nya piperazinderivat
SE7709051L (sv) Sett att framstella prostanderivat
SE7704055L (sv) Sett att framstella nya naftalenderivat
SE7712732L (sv) Sett att framstella heparin
SE7801949L (sv) Nytt pyridyl-piperazinderivat jemte sett att framstella detsamma
SE441680B (sv) Sett att framstella kolecystokininpankreozymin-oktapeptidamidsulfatester
SE432930B (sv) Sett att framstella 2-oxo-2,3-dihydro-3-bens/b/tiofenkarboxamid-derivat
SE430694B (sv) Sett att framstella 4-desacetoxivinkristin

Legal Events

Date Code Title Description
SPCF Application for supplementary protection certificate filed

Free format text: 7614201

SPCG Supplementary protection certificate granted

Free format text: 7614201, EXPIRES: 20011217

NAL Patent in force

Ref document number: 7614201-7

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7614201-7

Format of ref document f/p: F